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New semiquantitative ultrasonographic score for
peripheral arterial disease assessment and its
association with cardiovascular risk factors
Luca Santoro1, Pietro Manuel Ferraro2, Andrea Flex1, Antonio Nesci1, Giuseppe De Matteis1,
Angela Di Giorgio1, Vincenzo Zaccone1, Giovanni Gambaro2, Antonio Gasbarrini1 and Angelo Santoliquido1
The data concerning the distribution, extent and progression of peripheral arterial disease (PAD), as well as its association
with traditional cardiovascular (CV) risk factors, have generally been obtained from studies of patients in advanced stages
of the disease undergoing surgical or endovascular treatment. In this study, we have introduced a new semiquantitative
ultrasonographic score (ultrasonographic lower limb atherosclerosis (ULLA) score) that is able to categorize lower limb
atherosclerotic lesions at all stages of PAD. We then associated these ultrasonographic categories with a CV risk profile. We
enrolled 320 consecutive subjects with symptoms suggestive of PAD or with known CV risk factors referring to our angiology
unit between 1 July 2014 and 30 June 2015 for ultrasonographic evaluation of the lower limb arteries. Femoropopliteal and
run-off segments were categorized together and separately based on their ultrasonographic characteristics. In univariate and
multivariate analyses, the ULLA scores were significantly associated with the main CV risk factors, that is, age, male gender,
cigarette smoking, arterial hypertension, diabetes, dyslipidemia, sedentary lifestyle, previous CV events and family history of
CV disease, and also confirming the specific association of single risk factors with different segments of lower limb arteries.
The proposed ULLA score enables a complete evaluation of the entire lower limb atherosclerotic burden, extending the results
concerning the association of PAD with CV risk factors to all stages of the disease, including the early stages. It can be feasible
that this new score will facilitate better evaluation of the progression of PAD and its prospective role in CV risk stratification.
Hypertension Research advance online publication, 14 July 2016; doi:10.1038/hr.2016.88
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INTRODUCTION
Atherosclerosis is a systemic, multifocal disease that represents the
leading cause of death in Western countries.1 The risk factors
contributing to its distribution, extent and progression in different
organs (i.e., the heart, brain or limbs) and different segments (large
and small vessels) are not identical.2–4 In particular, smoking and
diabetes mellitus seem to be more strictly associated with lower limb
atherosclerosis (termed peripheral arterial disease (PAD)), with respect
to coronary heart and cerebrovascular districts, independently of the
severity of the underlying atherosclerosis.5 Moreover, there are striking
dissimilarities between the arterial regions of the lower extremities:
smoking and hypercholesterolemia are closely related to the
involvement of the iliac and femoropopliteal (proximal) district,
whereas diabetes mellitus is closely related to the involvement of the
infrageniculate (distal) district.6
The findings relating to the distribution pattern of peripheral
atherosclerotic lesions generally have been obtained from studies of
patients undergoing surgical or endovascular treatment for advanced
stages of PAD (generally Fontaine stages III–IV), which correspond to
the detection of hemodynamically significant lesions through
instrumental imaging. Moreover, the diagnostic techniques used in
these studies are typically limited to angiography or ankle–brachial
index (ABI) evaluation, which are two methods that do not provide
information about early atherosclerotic lesions and about the entire
atherosclerotic burden. In medicine, there is an increased need to
identify early lesions, which act as markers of vascular damage
associated with increased cardiovascular (CV) risk; thus, searching
only for signs of advanced PAD that can result in superficial findings.
These considerations are relevant considering the recent involvement
of PAD in CV risk stratification. In recent years, several imaging
techniques, including ultrasonography, have been suggested to
distinctly evaluate the entire arterial tree of the lower limbs, enabling
atherosclerotic lesions to be identified at all disease stages.
Currently, no data evaluating the association between traditional
CV risk factors and PAD consider all stages of PAD, including early
atherosclerotic lesions.
Therefore, the aims of this study are (i) to propose a new
ultrasonographic score, the ULLA (ultrasonographic lower limb
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atherosclerosis) score, which categorizes atherosclerotic lesions of the
lower limbs at all stages of PAD, and (ii) to associate these
ultrasonographic categories with CV risk profiles.
PATIENTS AND METHODS
Patients
All consecutive subjects with symptoms suggestive of PAD or with known CV
risk factors who were referred to our angiology unit between 1 July 2014 and 30
June 2015 for ultrasonographic evaluation of the lower limb arteries were
recruited for the study. The exclusion criterion was age o18 years.
CV risk factors included in the statistical model were age, gender, diabetes
mellitus status, arterial hypertension status, dyslipidemia status, body mass
index (BMI), cigarette smoking modeled as both number (packs per year) and
smoking status (‘never’, ‘former’ and ‘active’), sedentary lifestyle, previous CV
events and family history of CV disease. The presence of diabetes mellitus status
was determined based on the following indicators: fasting plasma glucose
concentration (after 8 or more hours of no caloric intake) ⩾ 126 mg dl− 1;
plasma glucose concentration ⩾ 200 mg dl− 1 2 h after ingesting a 75 g oral
glucose load in the morning after an overnight fast of at least 8 h; symptoms of
hyperglycemia (e.g., polyuria, polydipsia, polyphagia) and a random (casual,
non-fasting) plasma glucose concentration ⩾ 200 mg dl− 1; or hemoglobin A1c
level ⩾ 6.5%.7 The presence of arterial hypertension status was defined by
systolic blood pressure 4140 mm Hg and/or diastolic blood pressure
490 mm Hg or in case of consumption of any antihypertensive drug.8 The
presence of dyslipidemia status was defined by low-density lipoprotein
cholesterol level 4130 mg dl− 1, total cholesterol level 4200 mg dl− 1,
triglyceride level 4150 mg dl− 1, high-density lipoprotein cholesterol level
o50 mg dl− 1 or in case of consumption of any lipid-lowering drug.9
Ultrasound lower limb evaluation
Ultrasonographic examination was performed using a high-resolution Philips
iU22 sonograph (Philips Medical Systems, Monza, Italy) and a linear 9–3 MHz
transducer. Patients were placed in a supine position; the femoropopliteal and
run-off segments were continuously scanned from the subinguinal region to the
paramalleolar region with axial and sagittal scans. All segments were examined
for their parietal characteristics, especially the presence of vessel wall
calcifications and/or atherosclerotic plaques. In addition, flow velocity
measurements were obtained using spectral Doppler imaging with an
insonation angle of 60° and color Doppler imaging. Arteries were grouped
into femoropopliteal or proximal (common, superficial and deep femoral
arteries, popliteal artery) and infrageniculate or distal (tibiofibular trunk,
anterior and posterior tibial arteries, fibular artery) districts.
A new ultrasonographic, semiquantitative scoring system for disease severity
assessment, the ULLA score, was proposed for assessing the proximal and distal
districts. The lesions in the proximal district were categorized into six groups:
(I) normal parietal characteristics (no vessel wall calcifications and/or
atherosclerotic plaques), with normal flow velocity measurements; (II) presence
of non-stenotic parietal calcifications, with normal flow velocity measurements;
(III) presence of atherosclerotic plaques stenosing the artery by not 430%,
with normal flow velocity measurements; (IV) presence of stenosing
atherosclerotic plaques narrowing the lumen 430% but o70%, with normal
flow velocity measurements; (V) presence of stenosing atherosclerotic plaques
narrowing the lumen 470%, with alteration of flow velocity measurements;
and (VI) complete occlusion of the lumen.
The lesions in the distal district were categorized into five groups: (I) normal
parietal characteristics (no vessel wall calcifications and/or atherosclerotic
plaques), with normal flow velocity measurements; (II) presence of
non-stenotic parietal calcifications, with normal flow velocity measurements;
(III) presence of non-stenotic atherosclerosis, with normal flow velocity
measurements; (IV) presence of atherosclerosis, with alteration of flow velocity
measurements; and (V) complete occlusion of the lumen. Non-stenotic distal
district lesions characterized by normal flow velocity measurements were
grouped together because of the reduced accuracy of this tool when making
precise stenoses evaluations in small vessels and in cases of poor clinical
significance.
All scans were performed by the same experienced vascular sonographer.
Statistical analysis
Between-group differences were assessed using an analysis of variance for
normally distributed continuous variables, the Kruskal–Wallis test for
non-normally distributed continuous variables and a χ2 test for nominal
variables. The ULLA total severity score was defined as the highest of the
Table 1 Baseline characteristics of the study population by ULLA total severity score
Total severity score
I II III IV V VI P-value
N 36 86 89 27 63 19
Age, mean (s.d.) 59 (10) 69 (10) 69 (9) 72 (7) 74 (8) 74 (8) o0.001
Gender o0.001
F 29 (81%) 62 (72%) 49 (55%) 9 (33%) 22 (35%) 3 (16%)
M 7 (19%) 24 (28%) 40 (45%) 18 (67%) 41 (65%) 16 (84%)
Altered ABI 2 (6%) 7 (8%) 10 (11%) 7 (26%) 34 (54%) 19 (100%) o0.001
BMI, mean (s.d.) 27.2 (5.1) 27.3 (3.9) 27.7 (4.9) 28.9 (4.9) 26.1 (3.5) 25.8 (2.9) 0.043
Packs per year, median (IQR) 3 (0, 11) 0 (0, 8) 15 (0, 30) 11 (0, 36) 23 (0, 38) 45 (18, 60) o0.001
Smoking status o0.001
Never 13 (36%) 55 (64%) 32 (36%) 9 (33%) 16 (25%) 2 (11%)
Former 14 (39%) 21 (24%) 40 (45%) 14 (52%) 35 (56%) 12 (63%)
Active 9 (25%) 10 (12%) 17 (19%) 4 (15%) 12 (19%) 5 (26%)
Hypertension 15 (42%) 53 (62%) 65 (73%) 19 (70%) 55 (87%) 15 (79%) o0.001
Diabetes 3 (8%) 24 (28%) 26 (29%) 15 (56%) 31 (49%) 6 (32%) o0.001
Dyslipidemia 17 (47%) 49 (57%) 60 (67%) 16 (59%) 39 (62%) 12 (63%) 0.42
CV family history 28 (78%) 67 (78%) 75 (84%) 16 (59%) 50 (79%) 16 (84%) 0.15
Sedentary lifestyle 5 (14%) 18 (21%) 27 (30%) 5 (19%) 26 (41%) 5 (26%) 0.025
CV events 3 (8%) 12 (14%) 19 (21%) 8 (30%) 24 (38%) 10 (53%) o0.001
Abbreviations: ABI, ankle–brachial index; BMI, body mass index; CV, cardiovascular; ULLA, ultrasonographic lower limbs atherosclerosis.
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proximal or distal scores, regardless of the involvement of one or both legs;
moreover, the proximal and distal scores were evaluated separately.
Associations between each CV risk factor and the ULLA scores were assessed
with ordered logistic models. Models were further adjusted for age, gender and
BMI, and the univariate and adjusted estimates of association are presented.
The full set of analyses was repeated after the exclusion of participants with
altered ABI (i.e., ABIo0.9). All statistical analyses were performed with Stata
MP 13.0 (StataCorp, College Station, TX, USA). A two-tailed P-value o0.05
was regarded as statistically significant.
Ethical approval
Written informed consent was obtained from all participants before their
enrollment in the study. The study was performed in accordance with the
Declaration of Helsinki and was approved by the ethics committee of the
Catholic University of Rome (ethics committee reference number: 14725/2014).
RESULTS
Overall, 320 participants were included in the study; their baseline
characteristics by total severity score are reported in Table 1.
Univariate and multivariate estimates of the association between CV
risk factors and ULLA scores (total severity score and proximal and
distal districts scores) are reported in Table 2.
In the univariate analyses, all the ULLA scores were significantly
associated with age and male gender, but not with BMI. After
adjusting for age, gender and BMI, there was a statistically significant
association between the total severity score and pack-years of
smoking (Po0.001), smoking status (Po0.001), arterial hypertension
(P= 0.001), diabetes (P= 0.004), dyslipidemia (P= 0.04), sedentary
lifestyle (P= 0.02) and previous CV events (P= 0.01); the association
with family history of CV disease was marginally significant (P= 0.05).
When the proximal and distal districts were considered separately,
smoking status (P= 0.01) and dyslipidemia (P= 0.02) were selectively
associated with the proximal district score, whereas family history
of CV disease (P= 0.03) and sedentary lifestyle (P= 0.002) were
selectively associated with the distal district score. Packs per year
of smoking, arterial hypertension and diabetes were significantly
associated with both proximal and distal district scores. However,
for arterial hypertension, the magnitude of the association was larger
for the proximal district score (odds ratio (OR) 2.26 vs. 1.90), whereas
for diabetes it was larger for the distal district score (OR 2.41 vs. 1.75).
After excluding those participants with altered ABI (n= 79) or
PAD symptoms (n= 39) from the analysis, the results remained
substantially unaltered, except for previous CV events, which was no
longer associated with the scores of subjects with normal ABI
(Tables 3 and 4).
DISCUSSION
Most studies of atherosclerosis identify patients as affected by
PAD only if they report symptoms suggestive of PAD or provide
instrumental demonstration of lower limb perfusion deficits.
This trend may explain why PAD remains, probably, the most
underdiagnosed and least aggressively managed atherosclerotic disease.
However, several studies have indicated that patients with PAD have
an increased risk for all-cause mortality and for death from coronary
heart disease than those without PAD.10–12 It is important to address
the presence of atherosclerotic lesions in the lower limb districts before
they become apparent as a clinical PAD syndrome. Currently, the
presence of subclinical vascular damage represents a topic of great
interest; examples include the pivotal role of carotid intima–media
thickness in stratifying patients who are candidates for therapy
initiation and the role of arterial stiffness in predicting future CV
events in patients with coronary artery disease.13–15
The lack of an adequate evaluation of early atherosclerotic lesions of
the lower limbs is a serious shortcoming, especially when considering
the possible association of PAD with known CV risk factors and the
possible predictive role of PAD and its involvement in global CV risk
stratification.
To overcome these limits, in this study, we introduced a new
ultrasonographic score, the ULLA score, which facilitates the
categorization of atherosclerotic lesions of the lower limbs in all stages
of PAD and associating these ultrasonographic categories with CV risk
profiles. The main finding of our study is that the total severity index
of the proposed ultrasonographic score is associated with age and male
gender and with the other main traditional CV risk factors, that is,
smoking, hypertension, diabetes, dyslipidemia, sedentary lifestyle and
previous CV events, even after adjustment for age, gender and BMI.
Table 2 Associations between risk factors and ULLA scores
Total severity Proximal Distal
Univariate OR Multivariate OR Univariate OR Multivariate OR Univariate OR Multivariate OR
Age (1 year) 1.08 (1.06, 1.10) — 1.07 (1.05, 1.09) — 1.10 (1.08, 1.13) —
Male gender 4.17 (2.74, 6.34) — 3.99 (2.61, 6.09) — 3.21 (2.10, 4.93) —
BMIa (1 kg m−2) 0.97 (0.93, 1.02) — 0.97 (0.93, 1.02) — 0.97 (0.92, 1.02) —
Packs per year (1U) 1.03 (1.02, 1.04) 1.02 (1.02, 1.03) 1.03 (1.02, 1.04) 1.03 (1.02, 1.04) 1.02 (1.01, 1.03) 1.02 (1.01, 1.03)
Smoking statusb
Former 2.73 (1.76, 4.25) 1.62 (0.95, 2.78) 2.71 (1.74, 4.22) 1.61 (0.94, 2.75) 1.87 (1.19, 2.92) 1.14 (0.65, 2.00)
Active 1.94 (1.10, 3.44) 2.65 (1.40, 5.01) 2.10 (1.17, 3.76) 2.77 (1.45, 5.29) 1.03 (0.57, 1.87) 1.58 (0.81, 3.11)
Hypertension 2.91 (1.87, 4.53) 2.23 (1.40, 3.57) 2.96 (1.90, 4.63) 2.26 (1.41, 3.63) 2.65 (1.68, 4.18) 1.90 (1.17, 3.10)
Diabetes 2.36 (1.55, 3.58) 1.94 (1.24, 3.02) 2.13 (1.40, 3.25) 1.75 (1.12, 2.73) 2.71 (1.75, 4.20) 2.41 (1.50, 3.87)
Dyslipidemia 1.34 (0.90, 2.00) 1.52 (1.01, 2.30) 1.48 (0.99, 2.22) 1.62 (1.08, 2.45) 1.04 (0.69, 1.57) 1.05 (0.68, 1.61)
CV family history 1.00 (0.62, 1.61) 1.63 (0.99, 2.67) 0.94 (0.59, 1.52) 1.38 (0.85, 2.26) 0.96 (0.59, 1.57) 1.76 (1.04, 2.96)
Sedentary 1.82 (1.18, 2.83) 1.77 (1.12, 2.81) 1.41 (0.91, 2.19) 1.30 (0.82, 2.07) 2.26 (1.42, 3.58) 2.21 (1.34, 3.64)
CV events 3.33 (2.07, 5.36) 1.95 (1.17, 3.23) 3.69 (2.28, 5.99) 2.22 (1.33, 3.72) 2.98 (1.83, 4.83) 1.77 (1.04, 3.00)
Abbreviations: BMI, body mass index; CV, cardiovascular; OR, odds ratio; ULLA, ultrasonographic lower limbs atherosclerosis.
aMultivariate models adjusted for age, gender and BMI.
bReference group, never smoked.
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Moreover, our data confirm that specific CV risk factors are selectively
associated with the proximal or distal districts; in particular, smoking
status and dyslipidemia are selectively associated with the proximal
district score, whereas CV family history and sedentary lifestyle are
selectively associated with the distal district score. Packs per year of
smoking, hypertension and diabetes are significantly associated with
both the proximal and distal district scores. However, for hyperten-
sion, the magnitude of the association is larger for the proximal
district score, whereas for diabetes it is larger for the distal district
score. Numerous hypotheses have been proposed to explain the site
selectivity of atherosclerotic lesions, including hemodynamic stress
related to arterial geometry and anatomic, cellular or biochemical
variations in the arterial wall.16
These findings confirm what is already known about the correlation
between PAD and CV risk factors and with regard to specific districts
and single CV risk factors. The findings extend the relationships
established in previous studies to all stages of PAD, including early,
asymptomatic stages. The current data, in fact, generally have been
obtained from studies of patients undergoing endovascular treatment
for advanced stages of PAD (generally Fontaine stages III–IV), which
correspond to the detection of hemodynamically significant lesions
through instrumental imaging. Moreover, the diagnostic tool used in
most studies has been angiography, which is considered the gold
standard for grading atherosclerotic lesions of the lower extremities.17
Nonetheless, some limitations for this technique must be considered.
First, angiography only allows the specific study of the proximal
arteries, with segments distal to the popliteal artery often not
considered because of their relatively poor visualization. Moreover,
in many angiographic studies, disease severity was based on the number
of occlusions, and the atherosclerotic pattern was defined only by the
endovascular target lesions treated.18 Finally, in several studies, subjects
with stenosis that did not reach 50% in any of the segments of the lower
Table 3 Associations between risk factors and ULLA scores among participants with normal ABI
Total severity Proximal Distal
Univariate OR Multivariate OR Univariate OR Multivariate OR Univariate OR Multivariate OR
Age (1 year) 1.08 (1.05, 1.11) — 1.08 (1.05, 1.11) — 1.11 (1.07, 1.14) —
Male gender 3.16 (1.94, 5.15) — 2.93 (1.78, 4.80) — 2.72 (1.63, 4.54) —
BMIa (1 kg m−2) 1.02 (0.97, 1.07) — 1.02 (0.96, 1.07) — 1.02 (0.97, 1.08) —
Packs per year (1 U) 1.02 (1.01, 1.04) 1.03 (1.01, 1.04) 1.02 (1.01, 1.04) 1.02 (1.01, 1.04) 1.01 (1.00, 1.02) 1.02 (1.00, 1.03)
Smoking statusb
Former 2.14 (1.28, 3.58) 1.49 (0.81, 2.76) 1.92 (1.15, 3.22) 1.31 (0.72, 2.41) 1.67 (0.98, 2.84) 1.18 (0.62, 2.24)
Active 1.17 (0.61, 2.25) 1.95 (0.96, 3.97) 1.15 (0.59, 2.23) 1.80 (0.87, 3.70) 0.58 (0.29, 1.17) 1.09 (0.50, 2.37)
Hypertension 2.78 (1.68, 4.60) 2.17 (1.26, 3.75) 3.03 (1.82, 5.04) 2.35 (1.34, 4.10) 2.37 (1.39, 4.03) 1.61 (0.90, 2.87)
Diabetes 2.57 (1.55, 4.26) 2.32 (1.35, 3.99) 2.19 (1.31, 3.66) 1.95 (1.12, 3.39) 2.97 (1.74, 5.07) 2.75 (1.54, 4.90)
Dyslipidemia 1.63 (1.01, 2.63) 1.66 (1.01, 2.71) 1.86 (1.15, 3.01) 1.85 (1.13, 3.04) 1.17 (0.71, 1.93) 1.06 (0.63, 1.78)
CV family history 1.15 (0.65, 2.05) 1.94 (1.07, 3.53) 0.92 (0.51, 1.64) 1.30 (0.72, 2.38) 1.15 (0.63, 2.11) 2.13 (1.12, 4.05)
Sedentary 2.13 (1.27, 3.57) 1.84 (1.06, 3.17) 1.55 (0.93, 2.59) 1.23 (0.71, 2.12) 2.31 (1.34, 4.00) 1.94 (1.07, 3.51)
CV events 2.06 (1.14, 3.71) 1.12 (0.59, 2.12) 2.41 (1.30, 4.48) 1.37 (0.71, 2.66) 1.84 (0.99, 3.41) 1.03 (0.52, 2.02)
Abbreviations: ABI, ankle–brachial index; BMI, body mass index; CV, cardiovascular; OR, odds ratio; ULLA, ultrasonographic lower limbs atherosclerosis.
aMultivariate models adjusted for age, gender and BMI.
bReference group, never smoked.
Table 4 Associations between risk factors and ULLA scores among participants with no symptoms
Total severity Proximal Distal
Univariate OR Multivariate OR Univariate OR Multivariate OR Univariate OR Multivariate OR
Age (1 year) 1.08 (1.05, 1.10) — 1.07 (1.05, 1.10) — 1.11 (1.08, 1.13) —
Male gender 3.72 (2.37, 5.83) — 3.92 (2.48, 6.20) — 3.06 (1.92, 4.88) —
BMIa (1 kg m−2) 1.00 (0.95, 1.04) — 0.99 (0.95, 1.04) — 0.98 (0.94, 1.04) —
Packs per year (1 U) 1.03 (1.02, 1.04) 1.02 (1.01, 1.03) 1.02 (1.01, 1.04) 1.02 (1.01, 1.03) 1.02 (1.01, 1.03) 1.02 (1.01, 1.03)
Smoking statusb
Former 2.54 (1.58, 4.07) 1.55 (0.87, 2.75) 2.55 (1.58, 4.09) 1.48 (0.84, 2.61) 1.80 (1.11, 2.93) 1.08 (0.59, 1.97)
Active 1.48 (0.80, 2.72) 2.18 (1.11, 4.27) 1.65 (0.88, 3.09) 2.44 (1.23, 4.86) 0.75 (0.39, 1.44) 1.25 (0.60, 2.58)
Hypertension 3.03 (1.90, 4.84) 2.17 (1.32, 3.59) 3.01 (1.88, 4.82) 2.12 (1.28, 3.52) 2.76 (1.69, 4.51) 1.83 (1.08, 3.11)
Diabetes 2.87 (1.81, 4.57) 2.26 (1.38, 3.70) 2.43 (1.53, 3.87) 1.85 (1.13, 3.03) 3.52 (2.16, 5.74) 2.91 (1.72, 4.93)
Dyslipidemia 1.45 (0.94, 2.23) 1.54 (0.99, 2.40) 1.53 (0.99, 2.36) 1.53 (0.98, 2.39) 1.09 (0.70, 1.71) 1.06 (0.66, 1.69)
CV family history 0.87 (0.52, 1.4) 1.46 (0.86, 2.47) 0.80 (0.48, 1.32) 1.20 (0.72, 2.02) 0.91 (0.54, 1.53) 1.75 (1.01, 3.05)
Sedentary 2.07 (1.27, 3.36) 1.96 (1.17, 3.28) 1.53 (0.95, 2.48) 1.35 (0.81, 2.25) 2.32 (1.39, 3.86) 2.17 (1.25, 3.76)
CV events 3.50 (2.06, 5.96) 2.15 (1.22, 3.78) 4.20 (2.43, 7.27) 2.49 (1.39, 4.45) 3.35 (1.95, 5.74) 2.10 (1.17, 3.77)
Abbreviations: ULLA, ultrasonographic lower limbs atherosclerosis; BMI, body mass index; CV, cardiovascular; OR, odds ratio.
aMultivariate models adjusted for age, gender and BMI.
bReference group, never smoked.
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limb arterial tree were excluded.19 Consequently, angiography does not
provide information about early atherosclerotic lesions, and the entire
atherosclerotic burden is often not considered for analysis.
Other studies have used noninvasive techniques to assess PAD by
detecting perfusion effects rather than the degree or site of stenosis
within single arteries. Most of these include ABI evaluation,
a measurement comparing the ankle systolic blood pressure to the
brachial artery systolic blood pressure. This test is simple, noninvasive,
risk free and inexpensive, and with an ABI value o0.90 indicative of
PAD, it has acceptable diagnostic performance properties for PAD
screening (sensitivity 79–95%; specificity 95–100%).20,21 However,
ABI results are abnormal only in the presence of advanced arterial
lesions able to reduce ankle systolic blood pressure; therefore, early
atherosclerotic lesions of the lower limbs cannot be detected by ABI
measurement. Moreover, ABI could produce ‘pseudonormal’ values in
the presence of arterial stiffening; thus, ABI is an imperfect marker of
lower limb perfusion, especially in diabetic patients.22
As mentioned above, the proposed ULLA score overcomes these
limitations, allowing a complete evaluation of the entire lower limb
atherosclerotic burden and extending the results to all stages of PAD,
including early stages. Moreover, after excluding patients with altered
ABI or with symptoms suggestive of PAD, our results remained
substantially unchanged, confirming the robustness of the proposed
score even in the early, preclinical stages of PAD. This result is
especially important when we consider that only 10% of patients
affected by PAD have the classic symptoms of intermittent
claudication; most patients report atypical symptoms or no symptoms
at all.23 The only reported difference is represented by the loss of
association between previous CV events and ULLA scores in the 241
patients with normal ABI, even after adjusting for age and the other
traditional CV risk factors. It is plausible that this result reflects the
reduced systemic involvement of vascular damage in these patients.
Considering PAD at all stages of the disease can have a role also in
the recent research revealing the role of PAD involvement in CV risk
stratification. Risk stratification in CV disease prevention represents a
major goal for twenty-first century medicine. Assessment of traditional
CV risk factors, such as blood pressure and low-density lipoprotein
cholesterol levels, remains the cornerstone of risk estimation; however,
a residual risk may remain even after controlling for traditional
CV risk factors. Therefore, new markers, mainly those related to
inflammation and genetic profiles, have recently been added to
scoring systems to better assess the risk of CV disease, together
with instrumental techniques for measuring asymptomatic organ
damage.24,25 Among these instrumental techniques, those techniques
that evaluate the cardiac and carotid districts seem to be the most
effective. In particular, the independent prognostic value of carotid
ultrasonography with evaluation of carotid intima–media thickness
and plaques in predicting CV events has been widely
demonstrated.26–28 Recently, the presence of PAD has also been
considered in the assessment of organ damage to better define the
existing CV risk profile. Patients affected by ABI-assessed PAD have
higher CV mortality and morbidity than age-matched controls with-
out PAD, even after adjusting for traditional CV risk factors using the
Framingham Risk Score, and these findings are similar for individuals
with symptomatic and asymptomatic PAD.10–12 Studies involving
ultrasound evaluation of the lower limb districts have shown the
femoral intima–media thickness measurement to be an indicator of
symptomatic coronary atherosclerosis.29–32
The proposed ULLA score for PAD, which is able to categorize
earlier stages of the disease, could change the predictive value of PAD
in assessing CV risk. In particular, our findings could improve the
identification of individuals with a low-moderate 10-year risk for
CV disease based on classical scoring systems but a moderate-high
lifetime risk, allowing these individuals to benefit from early
interventions designed to prevent progression to the high-risk group
in later life. Moreover, exploring the possible presence of subclinical
atherosclerosis in the lower limb districts could be of interest because
multiple organ damage carries a worse prognosis than single organ
involvement.33,34 In individuals with one or more classical risk factors
who do not appear to have a high total CV risk according to current
methods of quantification, subclinical organ damage is common.
The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering
Arm demonstrated that treatment of patients with indicators of
subclinical CV disease could reduce CV events.35
Another important implication of the ULLA score is the ability to
compare the real association of CV risk factors with the atherosclerotic
lesion distribution in different districts. This association is often
deduced through instrumental methods with different sensitivities.36
Moreover, a complete tool for identifying PAD stages in all patients is
fundamental for the assessment of PAD progression; currently, most
studies conducted for this purpose have used only ABI or angiographic
evaluation, establishing that smoking and diabetes mellitus are the
most important factors in PAD progression.37,38 The use of a more
appropriate instrumental technique that is more accurate, especially in
identifying early lesions, could also facilitate the association of PAD
with novel biomarkers of the atherosclerosis process associated with
pathways of inflammation, lipoprotein and adipocyte metabolism,
hemodynamic stress, calcification and hemostasis.39,40
Certainly, the most interesting future research on the proposed
ULLA score will be studying its predictive properties with respect to
the risk of CV event development. In fact, it is well known that only a
small percentage of patients with PAD require lower extremity
intervention; thus, screening for PAD should be not beneficial as
much in reducing the risk of symptomatic PAD or ischemic limb
event, rather than it should be help identify those who need aggressive
preventive measures for CV and cerebrovascular risk reduction.
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